phiRO is @ESTRO_RT's Gold OA journal for research in medical physics & imaging in radiation oncology. New 2023 Impact Factor of 3.4!
Amsterdam, The Netherlands
Joined September 2019
- Tweets116
- Following46
- Followers198
- Likes75
New paper out🚨by Lambri et al. @HumanitasMilano in #phiRO!
doi.org/10.1016/j.phro.2024.…
They developed an #ML and Lean Six Sigma target PSQA program, implemented it clinically, and evaluated it over 6 months. #MedPhys #RadOnc
@MancosuPietro @ESTRO_RT @OncoAlert
🧵1/7
Results ➡️Good consistency between Measure and Control steps for complexity metrics and GPR prediction.
Corrective action improved expected GPR
6/7
This was one of our shortlisted papers for the phiRO award! see our 1-post summary here xitter.cf/PhiroTweets/status/178…
Check out this #ESTRO24 study on an MRI-compatible deformable phantom with integrated PSDs. It enhances real-time #dosimetry and enables investigation of the latest adaptive #radiotherapy #innovations.
👉bit.ly/4bUOJJa
#MedPhys #MedicalPhysics #MRLinac #radonc
Phiro Tweets retweeted
New in @PhiroTweets:
Quantitative imaging metrics correlated with rapid volume loss during #radiotherapy for head & neck cancer #hncsm including high density/proliferation image markers. FDG #PET correlated with regression in uni/multivariate analysis.
phiro.science/article/S2405-…
Phiro Tweets retweeted
📣 Join us for the 7th ESTRO Physics Workshop 2024: Science in Development!⏰Don't miss out on the application deadline: 31 July 2024
👉 Check out the programme: bit.ly/3VjwJTJ
#PhysicsWorkshop #medphys #MedicalPhysics #radonc
My impact factor stays very strong for 2023🦾 Thanks to all the #medphys people for submitting their excellent work 📰 for reviewing papers ✅ for reading 🤓 and for citing ✏️ the high impact science we publish!
We're pleased to announce phiRO's 2023 impact factor of 3.4, making it a leading journal in #medicalphysics. Achieved in just the 2nd year with an impact factor, highlighting our team's high-quality peer-review, benefiting authors & readers.
👉bit.ly/4blHDgA #Radonc
Phiro Tweets retweeted
Happy to share the first paper from Zuza's PhD journey! 🎉 Exponential decay fitting of ALC counts improved the prediction of RIL compared to traditional methods. This marks just the beginning of your PhD journey-excited to see where your research takes you next! 🔬☢️@PhiroTweets
Our article (first one from my PhD) is out! A short 🧵
phiro.science/article/S2405-…
Another #ESTRO2024 phiRO award shortlisted abstract was by Moritz Schneider (who asked not to share slides on SoMe).
Adaptive RT requires fast dose calc⏱️so they trained an NN to learn dose deposition mechanisms (in B field!)
👍performance for segments and fields compared to MC
One more #ESTRO2024 phiRO Award shortlisted abstract: "Genetically-based analysis of dose surface maps for assessing toxity post-RT: an innovative method" by Eliana Gioscio shows how to include patient genetic risk in voxel-based analysis.
Carlos E Cardenas presented their winning approach in ESTRO Auto-RTP challenge "1-Click Victory: Leading the ESTRO Auto-RTP Challenge with an Integrated Auto-Planning Pipeline" during #ESTRO2024 and got nominated for the phiRO award.
"AI informed discussion on how dose outside the PTV affects distant failure in SBRT NSCLC patients " by Denis Dudas was also nominated for the phiRO award at #ESTRO2024. The importance of confounding variables and correct stratification was demonstrated.
Another phiRO award nominee at #ESTRO2024 was "OAPT: feasibility of prompt-gamma verfication for CBCT-based adapted plan" by Stephanie Bertschi from OncoRay.
For corrected or virtual CBCTs, PGI/dose range shifts were minimal (on phantoms). Results on patient data coming soon!
"MLC tracking and dose accumulation validation on the MR-linac using a real-time deformable dosimeter" by Madelon van den Dobbelsteen from UMC Utrecht was also nominated for the phiRO award #ESTRO2024! Measurements agreed well with calculation for various forms of real-time ART.
Another top scoring (and winner of the phiRO award🥇) #ESTRO2024 abtract was "Partial adaptation for oAPT triggered by PGI" by Virginia Gambetta from #OncoRay. Adapting just between two fields was as good as full oAPT for 2-field prostate PT. No need to wait to start treating!
